title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
ETHICS APPROVAL | ONCOLOGY | All procedures were approved by the University of North Carolina at Chapel Hill Oncology Protocol Review Committee (LCCC1707) and Institutional Review Board (#16‐3409) and performed in accordance with ethical standards of the 1964 Helsinki Declaration and its later amendments. | PMC10469755 | |
CLINICALTRIALS.GOV IDENTIFIER | NCT03569605. | PMC10469755 | ||
ACKNOWLEDGMENTS | cancer | CANCER, RECRUITMENT | We are grateful for the valuable contributions of study team members, including Dr. Donald Rosenstein, Dr. Kristen Polzien, Dr. Lindsey Camp, Karen Hatley, Erin Coffman, and Susanna Choi. We thank Dr. Eliza Park, Dr. Andrew Smitherman, Lauren Lux, Dr. Allison Lazard, and community‐based organizations that helped with s... | PMC10469755 |
DATA AVAILABILITY STATEMENT | The data that support the findings of this study are available from the corresponding author upon reasonable request. The data are not publicly available due to privacy or ethical restrictions. | PMC10469755 | ||
REFERENCES | PMC10469755 | |||
Background | diphtheria, tetanus, poliomyelitis | DIPHTHERIA, TETANUS, POLIOMYELITIS, PERTUSSIS | Vaccination schedules differ from country to country. In France, the diphtheria, tetanus, pertussis, poliomyelitis (dTcaP) booster vaccine coverage for adults aged 25 has been lower than those recommended. We evaluated the impact of an awareness campaign undertaken by the French national health insurance system in 2021... | PMC10463893 |
Methods | A randomized, controlled study with adults residing in the Ardennes region was conducted to evaluate the effect on vaccine coverage of the booster vaccine reminder campaign carried out via letter and/or email and/or SMS. The randomization unit was the municipal administrative area (canton). Ten cantons were grouped int... | PMC10463893 | ||
Results | A total of 1,975 adults were included (INT: 67.3% vs. CON: 32.7%). Of them, 331 received a booster vaccine (INT: 17.4% vs. CON: 15.5%; p = 0.29), and 1,442 consulted a GP (INT: 73.7% vs. CON: 76.8%; p = 0.14). Those who consulted a GP had more frequent vaccine delivery (INT: 19.1% vs. CON: 10.5%; p < 0.0001). | PMC10463893 | ||
Conclusions | This study found that the awareness campaign run by the French national health insurance did not improve the uptake of the dTcaP booster and that there was a low rate of vaccinated adults aged 25 years. A GP consultation was associated with dTcaP booster vaccine delivery which may show that there is a need of involving... | PMC10463893 | ||
Keywords | PMC10463893 | |||
Background | diphtheria, tetanus, poliomyelitis | DIPHTHERIA, PERTUSSIS, TETANUS, POLIOMYELITIS, INFLUENZA | Vaccination schedules differ from country to country and are followed according to local recommendations. According to literature, the best scheduling model in Europe for the diphtheria, tetanus, pertussis and poliomyelitis (DTPP) vaccination in children as well as the influenza vaccination for people over 65 years is ... | PMC10463893 |
Methods | PMC10463893 | |||
Study design | A prospective, randomized, controlled study was conducted in the Ardennes region in 2021. Participants included were those aged 25 years in 2020, residing in the region in June 2021 and who had not had a dTcaP booster vaccine dispensed from a pharmacy between January 1, 2019 and June 1, 2021. Those that were not affili... | PMC10463893 | ||
Study variables | The randomization unit was a municipal administrative area known as the canton. Among the 19 cantons in the Ardennes region, participants were pooled out of 10 cantons that were randomly selected to constitute the intervention group (INT) and of nine cantons that made up the control group (CON). The choice of the canto... | PMC10463893 | ||
Data collection | Data was collected on the dispensing of the dTcaP booster vaccine by pharmacies and pro-pharmacies within 12 months that the information by the CPAM had been disseminated. Outcomes included the dTcaP booster vaccine delivery (which was assessed using the Club Inter Pharmaceutic (CIP) codes corresponding to the vaccine ... | PMC10463893 | ||
Ethical considerations | MAY | Data processing was carried out in compliance with the French regulations, in particular the General Data Protection Regulation (GDPR) 2016/679 of the European Parliament and the Council of April 27, 2016 applicable since May 25, 2018 as well as the Data Protection Act of January 6, 1978 (amended in 2018). Participants... | PMC10463893 | |
Statistical analysis | Data were described using numbers and percentages (%). The analysis of the outcomes consisted of a comparison between the percentage of dTcaP booster vaccine delivery and the percentage of GP visits in both the INT and CON groups using Chi-square tests. The significance level was set at 0.05. Statistical analysis was p... | PMC10463893 | ||
Results | Among the 2,653 adults included in this study, a total of 678 (25.6%) received a dTcaP booster vaccine from a pharmacy or pro-pharmacy in 2021. The remaining 1,975 eligible adults were identified by the local CPAM Pole (INT: 67.3% vs. CON: 32.7%) (Fig.
Study flow chart. *municipal administrative areas, CPAM; The dTcaP... | PMC10463893 | ||
Discussion | This study found that the awareness campaign run by the CPAM did not improve the uptake of the dTcaP booster for adults aged 25 years. These findings may be inconsistent with existing literature on the effectiveness of patient reminders for vaccinations [Since this study was conducted in 2021, the effects of the COVID-... | PMC10463893 | ||
Conclusions | Vaccination coverage of the dTcaP booster vaccine for 25-year-olds was low in the Ardennes region in France in 2021 and the awareness campaign run by the CPAM did not improve vaccine uptake. A GP consultation was associated with dTcaP booster vaccine delivery which may show that there is a need of involving GPs in vacc... | PMC10463893 | ||
Acknowledgements | The authors would like to thank Sarina Yaghobian and Marty Brucato from AcaciaTools for their reviewing and proofreading services. | PMC10463893 | ||
Authors’ contributions | CC, AH, BV, and AB participated in the design and helped interpret the results of the study as well as co-authored the article. AH, B-NP and SS participated in interpreting the results and contributed to the article’s writing. MC conducted the data collection, participated in the interpretation of the results, and co-a... | PMC10463893 | ||
Funding | None. | PMC10463893 | ||
Data availability | The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. | PMC10463893 | ||
Declarations | PMC10463893 | |||
Ethics approval and consent to participate | The study was conducted according to the Declaration of Helsinki guidelines and was approved by the Ethics Committee of | PMC10463893 | ||
Consent for publication | Not applicable. | PMC10463893 | ||
Competing interests | The authors declare no competing interests. | PMC10463893 | ||
References | PMC10463893 | |||
Subject terms | toxicities, cancer | ADVERSE EVENTS, CANCER, ADVERSE EVENT, SOLID TUMORS | This phase I, dose-escalation trial evaluates the safety of combining interferon-gamma (IFN-γ) and nivolumab in patients with metastatic solid tumors. Twenty-six patients are treated in four cohorts assessing increasing doses of IFN-γ with nivolumab to evaluate the primary endpoint of safety and determine the recommend... | PMC10374608 |
Introduction | osteopetrosis, death, cancers | CANCERS, CHRONIC GRANULOMATOUS DISEASE, SOLID TUMORS, OSTEOPETROSIS, DISEASES | Systemic immune checkpoint blockade (ICB) with drugs targeting the programmed death one (PD-1) pathway has revolutionized oncology. ICB offers the potential for some patients to experience durable anti-tumor responses; however, the majority of patients do not respond to single-agent ICBCytokines have been used for deca... | PMC10374608 |
Results | PMC10374608 | |||
Evaluable patients | Of the 26 patients accrued, all were evaluable for the primary safety analysis, and 23 were evaluable for exploratory efficacy analysis. Three patients in the 25 mcg/m | PMC10374608 | ||
Safety | All-grade, TNBC, DLTs, arthralgias | ADVERSE EVENTS, ADVERSE EVENT | Adverse events are summarized in Table All-grade adverse events occurring in >2 patientsAll grade adverse events occurring in > 2 patients attributed as at least possibly related to either drug and stratified by dose level and grade (* denotes dose limiting toxicity).There were three DLTs on the trial, one in the 75 mc... | PMC10374608 |
Efficacy | Twenty-three patients were evaluable for post-hoc exploratory efficacy analysis (Fig. | PMC10374608 | ||
Tumor biopsy analysis | tumor | SECONDARY, TUMOR | Planned secondary analyses of baseline tumor biopsies were compared to on-treatment biopsies collected after IFN-γ induction but prior to the administration of nivolumab. Of 21 patients with biopsy specimens evaluable for comparison of PD-L1 expression, TPS was >1% at baseline in 52% of patients (Supplementary Table | PMC10374608 |
Peripheral blood flow cytometry | As pre-specified we performed exploratory immune phenotyping of peripheral blood by multi-parametric flow cytometry to quantify subsets of monocytes and T cells, as well as their expression of various biomarkers. Across all four cohorts, while the frequency of classical monocytes remained relatively unchanged throughou... | PMC10374608 | ||
Impacts of IFN-γ and PD-1 blockade on monocytes. | Counts of (Several treatment-related changes were also observed in the peripheral T-cell populations. First, patients with longer duration of therapy tended to have higher numbers of CD4 | PMC10374608 | ||
Cytokine analysis | In an exploratory post-hoc analysis performed to assess the relative paucity of irAEs, we noted a statistically significant increase in plasma concentrations of six chemokines from baseline compared to both C1D1 and C2D15. These included known IFN-γ inducible chemokines CXCL9, CXCL10, and CXCL11 (Fig. | PMC10374608 | ||
Changes in IFNγ-associated chemokines after induction and addition of nivolumab. | Box plots displaying distribution of chemokine concentrations at three time points on study: baseline, C1D1, C2D15. | PMC10374608 | ||
Discussion | ascites, cancers, pleural effusion, DLTs, tumor, pleural or peritoneal disease, pleural disease, TNBC, RCC, esophagogastric carcinoma, tumors | PLEURAL EFFUSION, ASCITES, CANCERS, OVARIAN CANCER, TUMOR, PROLIFERATION, DISEASE, PLEURAL DISEASE, SOLID TUMOR, EFFUSIONS, PLEURAL EFFUSIONS, EVENTS, TUMORS, RCC | IFN-γ signaling plays an integral role in regulating immune activation and senescence in the TME, induces the expression of PD-L1 and is an essential component of an effective anti-tumor response with PD-1 pathway targeted agentsOverall, the combination was well tolerated. An increased burden of flu-like symptoms was p... | PMC10374608 |
Methods | PMC10374608 | |||
Study design | tumor, DLTs, toxicity, toxicities, Chase Cancer | FOX, TUMOR, DISEASE PROGRESSION | The study was conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki and was approved by the Fox Chase Cancer Center (FCCC) Institutional Review Board. This was a single-center, investigator-initiated phase I trial. The study was pre-registered at clinicaltrials.gov and fi... | PMC10374608 |
Study population | DISEASE | Eligible patients were ≥ 18 years of age, and could have any metastatic solid tumor type where there was demonstrated evidence of potential efficacy to anti-PD-1 pathway targeted therapy at the time of study design. All genders were eligible and patients self-reported. All patients needed to have received at least one ... | PMC10374608 | |
Study objectives | tumor, esophagogastric carcinoma | SECONDARY, TUMOR, METASTATIC CANCER | The primary endpoint of the study was the safety of the combination and to establish a RP2D. A final RP2D was to be established by the study steering committee at the conclusion of all accrued dose cohorts. Initial secondary efficacy endpoints included PFS, OS (median and at 1 year), and ORR for patients in the planned... | PMC10374608 |
Pre-specified exploratory correlative assessments | tumor, Tumor | PATHOLOGY, TUMOR, INFILTRATION, TUMOR | All patients were required to undergo a baseline tumor biopsy within 28 days prior to starting trial treatment, and then underwent a second tumor biopsy of the same site after the IFN-γ induction phase but before receiving nivolumab. Tumor specimens were to be evaluated by immunohistochemistry for PD-L1 expression and ... | PMC10374608 |
Post-hoc correlative analyses | In a post-hoc analysis prompted by clinical observations during the trial, cytokines in plasma were analyzed by the FCCC High Throughput Screening Facility utilizing the Human Chemokine Panel 40-plex (Bio-Plex Pro, Bio-Rad cat # 171AK99MR2) following manufacturer’s protocols and plates were read on a Bio-Plex 100/200 (... | PMC10374608 | ||
Statistical analysis | death | REGRESSION | PFS and OS in all evaluable patients were calculated using Kaplan-Meier curves. PFS was the interval to progression or death in those evaluable for efficacy. Duration of treatment was defined as the date from first dose of IFN-γ to progression, death, or completion of all treatments. The ORR was calculated using RECIST... | PMC10374608 |
Reporting summary | Further information on research design is available in the | PMC10374608 | ||
Supplementary information |
Supplementary InformationPeer Review FileReporting Summary | PMC10374608 | ||
Supplementary information | The online version contains supplementary material available at 10.1038/s41467-023-40028-z. | PMC10374608 | ||
Acknowledgements | Cancer | CANCER | The authors thank Irina Shchaveleva, Chun Zhou, and Judy Fang from the FCCC Immune Monitoring/Cell Sorting Facility for technical support. Jeffrey Sherman, Jeffrey Nieves, and Amy Grahn for support from Horizon Pharma. The NCI Cancer Center Support Grant (CA06927; FCCC) for support of core facilities utilized (Immune M... | PMC10374608 |
Author contributions | T.M., J.O. | PATHOLOGY | M.Z. is the corresponding author, conceptualized and designed the study, was the principal investigator of the clinical trial, coordinated data analysis and wrote and edited the manuscript. E.R.P. provided oversight for trial design and conduct, participated in data analysis and provided editorial support. K.S.C. coord... | PMC10374608 |
Peer review | PMC10374608 | |||
Data availability | Source data are provided with this paper. The minimum dataset necessary to interpret, verify and extend this research has been provided within the source data file wherever applicable. Per ICMJE guidelines de-identified participant data has been provided within the source data file. The study protocol has been provided... | PMC10374608 | ||
Competing interests | Chase Cancer | FOX | M.Z.: Institutionally directed research funding from Horizon Therapeutics and Bristol-Myers Squibb; Advisory Board Honorarium from Horizon Therapeutics. K.S.C.: Advisory Board Honorarium from Horizon Therapeutics, institutionally-directed research funding from Bristol-Myers Squibb. E.R.P.: Advisory Board Honorarium fro... | PMC10374608 |
References | PMC10374608 | |||
Purpose: | hearing preservation |
Editor-in-Chief: Ryan W. McCreeryEditor: Andrea Warner-CzyzCochlear implant (CI) recipients with hearing preservation experience significant improvements in speech recognition with electric–acoustic stimulation (EAS) as compared to with a CI alone, although outcomes across EAS users vary. The individual differences in... | PMC10166189 | |
Method: | Twenty-one participants were randomized at EAS activation to listen exclusively with a default or place-based map. For both groups, the unaided thresholds determined the acoustic cutoff frequency (i.e., > 65 dB HL). For default maps, the electric filter frequencies were assigned to avoid spectral gaps in frequency info... | PMC10166189 | ||
Results: | For participants with default maps, electric mismatch at 1500 Hz ranged from 2 to −12.0 semitones ( | PMC10166189 | ||
Conclusions: | The present sample of EAS users experienced better initial performance when electric mismatches were small or eliminated. These data suggest the utility of methods that reduce electric mismatches, such as place-based mapping procedures. Investigation is ongoing to determine whether these differences persist with long-t... | PMC10166189 | ||
Supplemental Material: | hearing preservation |
Adult cochlear implant (CI) recipients with hearing preservation experience significant improvements in speech recognition with electric–acoustic stimulation (EAS) as compared to preoperative performance or postactivation with a CI alone, although performance across EAS users remains widely variable (Maps that align t... | PMC10166189 | |
Method | Preliminary data were reviewed from an ongoing, prospective investigation of performance with default versus place-based maps for CI recipients. The study site institutional review board approved the procedures, and participants provided consent. Participants were randomized to listen exclusively with either a default ... | PMC10166189 | ||
Participants | Adult CI recipients were considered for inclusion if they underwent cochlear implantation at the study site, received a MED-EL lateral wall electrode array, were 18–80 years of age at the time of surgery, and presented with an unaided hearing threshold of ≤ 65 dB HL at 125 Hz in the implanted ear at device activation. ... | PMC10166189 | ||
Procedure | Unaided detection thresholds in the implanted ear were measured behaviorally using pure-tone stimuli presented over insert earphones at each interval. A low-frequency pure-tone average (LFPTA) was calculated from the unaided detection thresholds at 125, 250, and 500 Hz.Participants were fit with the ear-level Sonnet2Fo... | PMC10166189 | ||
Electric Frequency-to-Place Mismatch | Electric frequency-to-place mismatch was quantified as the semitone deviation between the electric center frequency and the SG place frequency for the electrode contact closest to the 1500-Hz cochlear place (~267°). The 1500-Hz place frequency was selected because it has been shown to be an important region for frequen... | PMC10166189 | ||
Data Analysis | Linear mixed models (LMMs) implemented in R using the | PMC10166189 | ||
Results | REGRESSION | The data included 21 participants (11 female) who were randomized to listen with either a default map (Demographic information for electric–acoustic stimulation users listening with either a default map or a place-based map.
Unaided air-conduction pure-tone detection thresholds for each participant at initial activatio... | PMC10166189 | |
Discussion | vowel and word recognition | SEPARATION | This report prospectively evaluated the early speech recognition for EAS users as a function of electric mismatch. Participants listened exclusively with either default maps (median electric mismatch: −5 semitones) or place-based maps that eliminated electric mismatches for low- to mid-frequency information. Poorer spe... | PMC10166189 |
Conclusions | These preliminary data suggest that EAS users experience better speech recognition when electric frequency-to-place mismatches are minimal and that the negative effects of larger magnitudes of electric mismatches are observed up to 6 months of listening experience. Methods to minimize electric mismatches, such as place... | PMC10166189 | ||
Data Availability Statement | The present preliminary data are available by e-mailing Margaret T. Dillon ( | PMC10166189 | ||
Supplementary Material | PMC10166189 | |||
Descriptive statistics of the vowel recognition and consonant–nucleus–consonant (CNC) word recognition (percent correct) for participants with default maps and participants with place-based maps at each interval. | Click here for additional data file. | PMC10166189 | ||
Acknowledgments | Deafness | DISORDERS, BROWN | The work was supported in part by a research grant provided to the university from MED-EL Corporation. Funding was also provided by the National Institute on Deafness and Other Communication Disorders (R21DC018389 awarded to Margaret Dillon and Kevin Brown, and T32DC005360 awarded to Paul Manis). The content is solely ... | PMC10166189 |
Footnote | Twelve semitones equal one octave. In the statistical models, electric mismatch was converted to an absolute value, removing the distinction between basal and apical shifts. | PMC10166189 | ||
References | PMC10166189 | |||
1. Introduction | tumor, Glioblastoma, aggressive cancer, BrICS-LIT, metabolic abnormalities | TUMOR, INFILTRATION, DISEASE, GLIOBLASTOMA, BRAIN TUMOR, AGGRESSIVE CANCER, BRAIN, TUMOR PROGRESSION, TUMOR RECURRENCE | Glioblastoma (GBM) is a fatal disease, with poor prognosis exacerbated by difficulty in assessing tumor extent with imaging. Spectroscopic MRI (sMRI) is a non-contrast imaging technique measuring endogenous metabolite levels of the brain that can serve as biomarkers for tumor extension. We completed a three-site study ... | PMC9964256 |
2. Materials and Methods | PMC9964256 | |||
2.1. Clinical Trial Treatment Protocol | IDH | After newly diagnosed GBM patients completed surgery, sMRI scans were acquired along with standard imaging to guide radiation treatment. At each participating site, a Siemens 3T scanner was used to perform an echo planar sMRI pulse sequence with GRAPPA parallelization with either a 32- or 20-channel head coil. The scan... | PMC9964256 | |
2.2. Follow-Up | BrICS-LIT, tumor | PATHOLOGY, TUMOR, BRAIN TUMOR | After patients completed RT, they returned for follow-up imaging every 2–3 months. At University of Miami and Emory University, follow-up occurred every 2 months, while patients at Johns Hopkins University had follow-up visits at 3-month intervals. Standard clinical follow-up was performed using the institution standar... | PMC9964256 |
2.3. Tumor Recurrence Determination | BrICS-LIT, tumor, necrosis | DISEASE PROGRESSION, TUMOR, PROLIFERATION, TUMOR PROGRESSION, NECROSIS, PATHOLOGY, TUMOR RECURRENCE | With BrICS-LIT, we graphed lesion volumes and BT-RADS scores over each patient’s follow-up period to observe long-term trends. As tumor-mimicking treatment effects such as pseudo-progression and radiation necrosis are commonly associated with high-dose radiation, we sought to use BrICS-LIT and clinical pathology report... | PMC9964256 |
2.4. Survival Analysis | All survival outcomes were assessed using the lifelines Python survival analysis library [ | PMC9964256 | ||
3. Results | PMC9964256 | |||
3.1. Survival Analysis | deaths | TUMOR PROGRESSION | Eighteen months after completing enrollment, the median PFS time was 16.6 months (As mentioned previously, fourteen out of nineteen patients with tumor progression had confirmed progression before their deaths. The criteria we outlined for determining progression were applied to this subgroup with additional details in... | PMC9964256 |
4. Discussion | tumor, toxicity, toxicities, edema, necrosis, BrICS-LIT, IDH | DISEASE PROGRESSION, TUMOR, RECURRENCE, EDEMA, TUMOR PROGRESSION, NECROSIS, PATHOLOGY, TUMOR RECURRENCE | In this study we describe the use of novel imaging visualization tools and structured reporting to analyze the results to date of our 30-patient clinical trial utilizing dose-escalated radiation guided by Cho/NAA sMRI maps. With standard-of-care therapy including standard RT with concurrent and adjuvant TMZ, GBM progno... | PMC9964256 |
5. Conclusions | glioblastoma, BrICS-LIT, necrosis | RECURRENCE, TUMOR PROGRESSION, NECROSIS, GLIOBLASTOMA, PATHOLOGY, TUMOR RECURRENCE | With a median time to follow-up of 20.3 months for censored patients, guiding escalated radiation dose to glioblastoma patients through spectroscopic MRI led to a median PFS of 16.6 months with a one-year incidence of recurrence from treatment of 30%, half that of standard therapy. These results are extremely encouragi... | PMC9964256 |
Author Contributions | Conceptualization, E.A.M., M.G., P.B.B., S.S.G., E.S., H.H., M.H., L.R.K., H.-K.G.S., H.S. and B.D.W.; Methodology, K.K.R., V.H., P.B.B., S.S.G., E.S., H.-K.G.S., H.S. and B.D.W.; Software, K.K.R., S.S.G., E.S., H.S. and B.D.W.; Validation, E.A.M., M.d.l.F., M.H., H.-K.G.S., H.S. and B.D.W.; Formal analysis, K.K.R., V.... | PMC9964256 | ||
Institutional Review Board Statement | The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Emory University (IRB00094188 on 4/14/2017). | PMC9964256 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC9964256 | ||
Data Availability Statement | The data presented in this study are available on request from the corresponding author. | PMC9964256 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC9964256 | ||
References | tumor | TUMOR, RESIDUAL TUMOR, BRAIN, TUMOR PROGRESSION, CAVITY | A comparison between the ratio map of choline to N-acetylaspartate (Cho/NAA) and T1-weighted contrast-enhanced (T1w-CE) imaging for three patients on the trial. For each patient, the top left image contains the Cho/NAA ratio map superimposed on the T1w image along with a contour encompassing all voxels with a Cho/NAA ≥... | PMC9964256 |
Purpose | We assessed the efficiency of low-dose recombinant human bone morphogenetic protein-2 (rhBMP-2) incorporated biomimetic calcium phosphate on β-tricalcium phosphate (β-TCP) (rhBMP-2/BioCaP/β-TCP) on bone formation in a model of socket preservation using cone beam computed tomography (CBCT) scanning and histological exam... | PMC10579201 | ||
Methods | tooth | Forty patients undergoing minimally invasive single-root tooth extraction for dental implantation were randomized to three groups according to the material used for socket preservation: filling with rhBMP-2/BioCaP/β-TCP, β-TCP, or natural healing (kept unfilled) (controls). The alveolar sockets (including the control g... | PMC10579201 | |
Results | ± | The mean (± standard deviation) changes of GVs of the CBCT scans at the central area of filled materials were as follows: 373.19 ± 157.16 in the rhBMP-2/BioCaP/β-TCP group, 112.26 ± 197.25 in the β-TCP group, and -257 ± 273.51 in the control group. The decrease of GVs in the rhBMP-2/BioCaP/β-TCP group as compared with ... | PMC10579201 | |
Graphical Abstract | PMC10579201 | |||
Keywords | PMC10579201 | |||
Introduction | tooth loss, tumors, neoplasm, trauma | ATROPHIC, NEOPLASM, TUMORS, DISEASES, HYDROXYAPATITE | Sufficient alveolar bone is a prerequisite for successful placement of dental implants. However, atrophic maxilla or mandible is a common finding in clinical practice due to tooth loss, trauma, tumors, neoplasm resection, or bone metabolism diseases [Different materials, such as autografts, allografts, and xenografts h... | PMC10579201 |
Methods | PMC10579201 | |||
Patient selection and study design | fasting blood glucose, Obese, inflammation, periodontitis, allergy, tooth, diabetes | UNCONTROLLED HYPERTENSION, PERIAPICAL PERIODONTITIS, OBESE, INFLAMMATION, PERIODONTITIS, ALLERGY, DIABETES | The study was approved by the Clinical Research Ethics Committees of the Academic Center for Dentistry of Amsterdam (code ACTA 202061), Vrije Universiteit Amsterdam, The Netherlands, and Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University, School of Medicine (code SH9H-2019-T231-4), China. This trial was co... | PMC10579201 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.